| Price | 1,759.00p on 06-10-2026 at 05:03:01 |
|---|---|
| Change | 0.00p 0% |
| Buy | 1,900.00p |
| Sell | 1,750.00p |
| Last Trade: | Unknown 52.00 at 1,759.00p |
| Day's Volume: | 0 |
| Last Close: | 1,759.00p |
| Open: | 0.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 1,592.00p - 2,282.00p |
| Market Capitalisation: | £70.48b |
| VWAP: | 0.00p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 52 | 1,759.00p | OTC Trade |
21:19:52 - 05-Oct-26 |
| Buy* | 200 | 1,759.00p | Automatic Execution |
16:36:51 - 05-Oct-26 |
| Buy* | 2,000 | 1,759.00p | Automatic Execution |
16:35:07 - 05-Oct-26 |
| Sell* | 1,749,082 | 1,759.00p | Uncrossing Trade |
16:35:04 - 05-Oct-26 |
| Buy* | 7 | 1,760.00p | SI Trade |
16:29:58 - 05-Oct-26 |
| Sell* | 308 | 1,760.00p | Automatic Execution |
16:29:45 - 05-Oct-26 |
| Sell* | 1,050 | 1,760.00p | Automatic Execution |
16:29:45 - 05-Oct-26 |
| Buy* | 961 | 1,760.00p | Automatic Execution |
16:29:44 - 05-Oct-26 |
| Buy* | 500 | 1,760.00p | Automatic Execution |
16:29:44 - 05-Oct-26 |
| Sell* | 567 | 1,759.50p | Automatic Execution |
16:29:43 - 05-Oct-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 1st Oct 2026 3:00 pm | RNS | Total Voting Rights |
| 24th Sep 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 22nd Sep 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 15th Sep 2026 7:00 am | RNS | GSK to acquire T cell-engager for multiple myeloma |
| 14th Sep 2026 7:00 am | RNS | Ris-Rez Positive Ph 3 OS Lung Cancer Data in China |
| 14th Sep 2026 7:00 am | RNS | Jideytro positive data for ROS1-positive NSCLC |
| 11th Sep 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 10th Sep 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 10th Sep 2026 7:00 am | RNS | Japan approval of Shingrix in a prefilled syringe |
| 9th Sep 2026 3:30 pm | RNS | Director/PDMR Shareholding |